ClinicalTrials.Veeva

Menu
U

Universitatsklinikum Leipzig AoR | Medizinische Klinik III - Rheumatologie

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Povorcitinib
JNJ-77242113
LGX818
Pemigatinib
Guselkumab
Vemurafenib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo
Recently updated

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment u...

Active, not recruiting
Psoriasis
Drug: Guselkumab
Drug: Placebo Injection

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatmen...

Enrolling
Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Drug: Cisplatin
Drug: Gemcitabine

This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemu...

Active, not recruiting
Melanoma
Drug: MEK162
Drug: vemurafenib

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatm...

Enrolling
Angioedema
Hives
Drug: Placebo
Drug: Povorcitinib

Trial sponsors

Incyte logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems